...
首页> 外文期刊>European Journal of Pharmacology: An International Journal >Effects of AMPA and clomethiazole on spreading depression cycles in the rat neocortex in vivo.
【24h】

Effects of AMPA and clomethiazole on spreading depression cycles in the rat neocortex in vivo.

机译:AMPA和氯甲噻唑对大鼠新皮层体内扩散性抑郁周期的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

In hippocampal slices, inhibition of AMPA receptors unmasks synaptic transmission via NMDA receptors, suggesting that AMPA receptor activation normally inhibits synaptic transmission via NMDA receptors. Activation of NMDA receptors is involved in the pathogenesis of cortical spreading depression (CSD) which has been implicated in the pathogenesis of migraine aura and neuronal damage from peri-infarct depolarizations. In this study we examined whether NMDA receptor transmission could be unmasked in the neocortex in vivo by AMPA receptor blockage and whether AMPA receptors could affect CSD induced by 200 mM KCl. We further compared the effects of AMPA to those of the NMDA receptor antagonist, 2-amino-5-phosphono-pentanoic acid (2AP5), and the GABA-mimetic drug clomethiazole. The NMDA receptor antagonist MK-801 did not affect the baseline somatosensory evoked potentials (SEPs). In a medium with no Mg(2+), the AMPA receptor antagonist 6,7-dinitroquinoxaline-2,3-dione (DNQX) caused marked reduction in the SEP size which subsequently recovered partially; MK-801 blocked these partially recovered SEPs. AMPA (50 muM but not at 5 muM or 250 muM) and 2AP5 (10 muM) significantly reduced the number of CSD cycles. The effect of AMPA was not changed by co-applying it with cyclothiazide, which blocks AMPA receptor desensitization. Clomethiazole (100 mg/kg i.p.) did not significantly affect the number of CSD cycles. Only 2AP5 significantly reduced the potentiation that follows CSD. We conclude that activation of AMPA receptors can suppress the actions of NMDA receptors in the neocortex; this could be an intrinsic protective mechanism against CSD and also provide a possible therapeutic strategy against CSD-related neurological conditions.
机译:在海马切片中,对AMPA受体的抑制作用掩盖了通过NMDA受体的突触传递,这表明AMPA受体激活通常会抑制通过NMDA受体的突触传递。 NMDA受体的激活与皮质扩散抑制(CSD)的发病机制有关,该机制与偏头痛先兆和梗死周围去极化引起的神经元损害的发病机制有关。在这项研究中,我们研究了AMPA受体阻滞在体内新皮层中NMDA受体的传递是否可以被掩盖,以及AMPA受体是否可以影响200 mM KCl诱导的CSD。我们进一步比较了AMPA与NMDA受体拮抗剂,2-氨基-5-膦酰基戊酸(2AP5)和GABA模拟药物克罗米唑的作用。 NMDA受体拮抗剂MK-801不影响基线体感诱发电位(SEPs)。在不含Mg(2+)的培养基中,AMPA受体拮抗剂6,7-二硝基喹喔啉-2,3-二酮(DNQX)导致SEP尺寸显着减小,随后部分恢复; MK-801阻止了这些部分回收的SEP。 AMPA(50μM,但不是5μM或250μM时不是)和2AP5(10μM)显着减少了CSD循环数。将AMPA与环噻嗪共同应用不会改变AMPA的作用,后者可阻止AMPA受体脱敏。氯甲唑(100 mg / kg腹腔注射)对CSD循环次数没有明显影响。只有2AP5显着降低了CSD后的增强作用。我们得出结论,AMPA受体的激活可以抑制新皮层中NMDA受体的作用。这可能是针对CSD的内在保护机制,也可能提供针对CSD相关神经系统疾病的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号